** Shares of vaccine maker Dynavax Technologies DVAX.O rise 1.8% to $14.26
** DVAX announces refinancing plan that extends the maturity of most of existing debt by four years
** Will issue $225 million of new convertible notes due in 2030
** New notes to replace about $185 million of existing convertible notes due in 2026, and an additional $40 million of new money will be raised
** New debt has a lower interest rate of 2% and a conversion price of $18.21/share; 30% premium to the stock's last close
** Co is buying back $8 mln of its own stock to keep the number of shares outstanding neutral
** DVAX to get $46.5 million from unwinding derivatives to partially offset the premium paid for the existing notes
** Co has 124.10 mln shares outstanding with a market cap of $1.7 bln - LSEG data
** DVAX fell 11.2% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。